

## **Paradigm's Nonclinical and Clinical Data Accepted for Presentations at Major International Conferences**

### **KEY HIGHLIGHTS**

---

- PAINWeek Conference 2023, 5–8 September: Abstract detailing the multiple mechanisms of action of injectable pentosan polysulfate sodium (iPPS) and its wide-ranging applications in the treatment of musculoskeletal disorders with pain and inflammation accepted for poster presentation at the conference.
- 30<sup>th</sup> Symposium on Glycosaminoglycans, 21–23 September 2023: Dr Ravi Krishnan has been invited to present virtually the mechanism of action of iPPS supporting the treatment of acute and chronic diseases at the exclusive symposium.
- American College of Rheumatology (ACR) Convergence Conference 2023: Two abstracts describing results from Paradigm's clinical and nonclinical studies in osteoarthritis have been accepted to the prestigious ACR conference to be held on 10–15 November.

---

**Paradigm Biopharmaceuticals Ltd (ASX:PAR) ("Paradigm" or "the Company")**, a late-stage drug development company focused on delivering new therapies to address unmet medical needs, is pleased to report three abstracts have been accepted for oral or poster presentations at the PAINWeek (Las Vegas) conference, the 30<sup>th</sup> Symposium on Glycosaminoglycans (Como, Italy) and the ACR Conference (San Diego). Conference material presented and accepted abstracts will be available on the Paradigm website following the conclusion of each conference.

**Paradigm Managing Director, Mr Paul Rennie said:** *"The acceptance of abstracts, posters and oral presentations at key conferences is significant as it is yet another form of peer review validation within the arthritis and pain management, scientific and clinical communities. Such validation is expected to support product adoption amongst prescribing physicians, once on market"*.

### **PAINWeek Conference 2023**

Dr Mukesh Ahuja, Paradigm Global Head of Osteoarthritis, will be presenting a poster at the PAINWeek Conference 2023 to be held in Las Vegas, USA from 5–8 September 2023. <https://www.painweek.org/conferences/painweek/painweek-2023>.

The poster will cover the multiple mechanisms of action of iPPS and its positive impact in wide-ranging applications in the treatment of musculoskeletal disorders with pain and inflammation. This is supported by clinical evidence from various Paradigm-sponsored clinical trials, which have pain-based outcomes, in OA (PARA\_008, PARA\_005), alpha virus (PARA\_004), and MPS type I (MPSV1\_001).

### **International Invite-Only Symposium on Glycosaminoglycans**

Dr Ravi Krishnan, Paradigm Chief Scientific Officer, has been invited to give a virtual presentation at the upcoming 30<sup>th</sup> Symposium on Glycosaminoglycans.

<https://www.ronzoni.it/glycosaminoglycan-symposium/>. The symposium will be held in Como, Italy, from 21–23 September 2023, and invites specialists from all over the world, including Paradigm and bene pharmaChem, to discuss both current and emerging topics of interest in the fields of chemistry, biochemistry, biology, pharmacology, and in the clinical applications of heparin and other glycosaminoglycans (**GAGs**). The symposium is organised by leading researchers from both the “G. Ronzoni” Institute for Chemical and Biochemical Research and the Universities of Bonn and Münster in Germany.

Dr Krishnan will be the first speaker of the day at the Saturday morning session and will present data on the various mechanisms of action of iPPS, with a 9:00am presentation titled: *“Pentosan polysulfate sodium, a glycosaminoglycan mimetic with multiple mechanisms of actions supporting the treatment of acute and chronic diseases.”*

Dr Kang Chen, a research chemist from the US Food and Drug Administration (**FDA**) will also be presenting on PPS during the Thursday afternoon session on strategic aspects of GAGs and GAG mimetics with their talk titled “NMR as a multi-attribute method in complex drug analysis: pentosan polysulfate sodium.”

The recent findings from the scientific article entitled *“Chemical and biological differences between original and mimetic pentosan polysulfates”*, a collaboration between bene pharmaChem, Kiel University and Paradigm will also be presented as a poster during the conference by Prof. Dr. Susanne Alban of Kiel University.

### ACR Convergence 2023

Drs Mukesh Ahuja and Ravi Krishnan will join an expected 10,000 rheumatological specialist attendees at ACR Convergence 2023, the annual meeting of the American College of Rheumatology and one of the world’s premier rheumatology conferences, to present two posters on:

- Therapeutic effects of iPPS on clinical and DMOAD outcomes in subjects with knee osteoarthritis.
  - The poster will present the promising clinical effects of iPPS, including pain reduction, improved function, and changes in disease biomarkers and MRI assessments in patients with knee OA. PARA\_008 clinical data at Day 56 and Day 168 will be presented.
- iPPS demonstrates durable effects on pain, function, and MRI (joint structure) in canine naturally occurring osteoarthritis.

The conference will be held 10–15 November at the San Diego Convention Center in San Diego, California.

### Upcoming news flow:

- The 12-month clinical outcome data from the PARA\_OA\_008 phase 2 clinical study is expected to be reported in September 2023. Data presented will include change from baseline in WOMAC pain and function data along with patient global impression of change (PGIC) and rescue medication measurements following iPPS treatment compared to placebo at the Day 365 time point.
- The quantitative analysis of MRI results from the day 168 timepoint of PARA\_OA\_008 is also expected to be reported in September 2023. Previously, Paradigm reported a semi-quantitative analysis of the structural observations following iPPS compared to placebo on cartilage volume, bone marrow lesions and marginal osteophytes. The quantitative analysis will provide further detailed

determination of the structural changes occurring in the joint following iPPS compared to placebo.

- Top-line data from the phase 2, double-blinded and randomised MPS VI clinical trial is expected during Q4 CY2023. Participants in the study are dosed weekly for 24 weeks with the primary endpoint being safety, followed by secondary endpoints of improvements in pain and function.
- The manuscript of PARA\_MPS\_001 Phase 2 clinical trial data is being completed and will be available following peer review and publication.
- The PARA\_OA\_008 manuscript has commenced drafting with sections from the day 365 data to be added once available. The manuscript will then be prepared for peer review and publication in a scientific journal.

## About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (**iPPS**) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of iPPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

## Forward Looking Statements

This Company announcement contains forward-looking statements, including statements regarding anticipated commencement dates or completions dates of preclinical or clinical trials, regulatory developments, and regulatory approval. These forward-looking statements are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties, and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this presentation. Readers are cautioned not to put undue reliance on forward-looking statements.

---

Approved for release by the Paradigm Board of Directors.

To learn more please visit: [www.paradigmbiopharma.com](http://www.paradigmbiopharma.com)

FOR FURTHER INFORMATION PLEASE CONTACT:

**Simon White**

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)